TELESIS BIO INC (TBIO)
US1920032000 - Common Stock
We assign a fundamental rating of 1 out of 10 to TBIO. TBIO was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of TBIO have multiple concerns. TBIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
TBIO had negative earnings in the past year.
In the past year TBIO has reported a negative cash flow from operations.
In the past 5 years TBIO always reported negative net income.
In the past 5 years TBIO always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -98.37%, TBIO is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
TBIO's Return On Equity of -521.49% is on the low side compared to the rest of the industry. TBIO is outperformed by 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -98.37% | ||
| ROE | -521.49% | ||
| ROIC | N/A |
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TBIO has a Gross Margin (47.88%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of TBIO has grown nicely.
The Profit Margin and Operating Margin are not available for TBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBIO has been increased compared to 1 year ago.
Compared to 1 year ago, TBIO has an improved debt to assets ratio.
2.2 Solvency
TBIO has an Altman-Z score of -6.48. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
TBIO has a Altman-Z score of -6.48. This is amonst the worse of the industry: TBIO underperforms 91.23% of its industry peers.
TBIO has a Debt/Equity ratio of 0.54. This is a neutral value indicating TBIO is somewhat dependend on debt financing.
TBIO has a Debt to Equity ratio of 0.54. This is in the lower half of the industry: TBIO underperforms 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.48 |
ROIC/WACCN/A
WACC14.42%
2.3 Liquidity
TBIO has a Current Ratio of 1.89. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
TBIO has a Current ratio of 1.89. This is in the lower half of the industry: TBIO underperforms 61.40% of its industry peers.
TBIO has a Quick Ratio of 1.72. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TBIO (1.72) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
The earnings per share for TBIO have decreased strongly by -1673.33% in the last year.
TBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.65%.
Measured over the past years, TBIO shows a very strong growth in Revenue. The Revenue has been growing by 61.13% on average per year.
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
3.2 Future
The Earnings Per Share is expected to decrease by -29.72% on average over the next years. This is quite bad
The Revenue is expected to decrease by -40.92% on average over the next years. This is quite bad
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TBIO's earnings are expected to decrease with -29.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
TBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELESIS BIO INC
NASDAQ:TBIO (9/27/2024, 8:22:41 PM)
After market: 2.85 -0.38 (-11.76%)3.23
-0.76 (-19.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.63%
Inst Owner Change-91.72%
Ins Owners5195.21%
Ins Owner Change0.05%
Market Cap5.72M
Analysts82.86
Price Target4.08 (26.32%)
Short Float %1%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-58.05%
Min EPS beat(2)-85.37%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-35.22%
Min EPS beat(4)-85.37%
Max EPS beat(4)-2.5%
EPS beat(8)4
Avg EPS beat(8)-9.5%
EPS beat(12)5
Avg EPS beat(12)-9.14%
EPS beat(16)8
Avg EPS beat(16)19.54%
Revenue beat(2)0
Avg Revenue beat(2)-63.87%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-51.12%
Revenue beat(4)0
Avg Revenue beat(4)-39.08%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)-2.28%
Revenue beat(8)2
Avg Revenue beat(8)-15.2%
Revenue beat(12)4
Avg Revenue beat(12)-9.56%
Revenue beat(16)5
Avg Revenue beat(16)-24.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-101.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-74.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.57 | ||
| P/tB | 1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-23.94
EYN/A
EPS(NY)-19.27
Fwd EYN/A
FCF(TTM)-12.84
FCFYN/A
OCF(TTM)-12.31
OCFYN/A
SpS9.9
BVpS5.62
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -98.37% | ||
| ROE | -521.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.88% | ||
| FCFM | N/A |
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40.13% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | -6.48 |
F-Score4
WACC14.42%
ROIC/WACCN/A
Cap/Depr(3y)185.64%
Cap/Depr(5y)117.94%
Cap/Sales(3y)13.42%
Cap/Sales(5y)9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.42%
OCF growth 3YN/A
OCF growth 5YN/A